|
summary: The authors reviewed the clinical trials of natalizumab a new medication for aggressive MS. They concluded that it is effective in reducing inflammation and disability but there is a 1/1000 risk of serious side effects.
authors: Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
source: Neurology. 2008 Sep 2;71(10):766-73
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
Clinical trial
Computerized
Disability
Inflammation
Multiple sclerosis
Neurology
Sclerosis
Urology
|
